Penbutolol in hypertension: evaluation of a new beta-adrenergic blocking drug.
The hypotensive effect of penbutolol, a new beta-adrenergic blocking drug, has been evaluated in a doulbe-blind crossover trial on 15 patients. Blood pressures were significantly lower during active drug treatment (P less than 0.001), the average reduction being: 1.7/0.9 kPa (13/7 mmHg) erect.
D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010394:Penbutolol / Q000627:therapeutic use*; D011412:Propanolamines / Q000627:therapeutic use*
D011412:Propanolamines; D010394:Penbutolol